Nobis Nobis Cartel windows 7 home premium activation key
Archivo del sitio

Rituximab in pemphigus

Pemphigus is a chronic, muco-cutaneous autoimmune blistering disorder; two main variants being pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype, varying between 75 to 92% of total pemphigus patients. Although no community based studies are undertaken

Etiquetado con: , , , , , , , ,
Publicado en: Todo el mundo, Noticias e información

Pemphigus: An Ayurvedic Approach

By Jay Glaser, M.D. Dr. Glaser is a board-certified internist, researcher and medical director at the Lancaster Ayurveda Medical Centers based in Sterling, MA. He can be reached at 978-422-5044. Answers to many questions about Ayurveda can be found on

Etiquetado con: , , , , , , ,
Publicado en: Médicos

Steroid-Induced Diabetes

by Christopher D. Saudek, M.D., Professor of Medicine, Johns Hopkins University School of Medicine, President, American Diabetes Association (July 2001). Steroids are commonly used in medicine, and their effects on blood sugar are often seriously underestimated. To give the bottom

Etiquetado con: , ,
Publicado en: Médicos

New Perspectives on the Cause of Blister Formation

By Sergei A. Grando, M.D., Ph.D., D.Sci. Professor of Dermatology University of California Davis NPF Advisory Board Member The goal of my research is to develop a safer and more rational treatment for pemphigus. I am deeply concerned that we,

Etiquetado con: , , , , , , ,
Publicado en: Médicos

Cellcept: A Promising New Immunosuppressive Drug

By Grant J. Anhalt, M.D. and Hossein Nousari, M.D.Johns Hopkins University, School of Medicine In February 1997, the FDA approved a new drug, mycophenolate mofetil (MFM, also known as Cellcept) with an approved indication for use in immunosuppression of patients

Etiquetado con: , , , , , , ,
Publicado en: Médicos

Bullous Disease Treatment

Grant J. Anhalt, MD Head, Dermatoimmunology Department Johns Hopkins University Baltimore, Maryland Vice President in charge of Scientific Affairs, The International Pemphigus Foundation

Prior to the introduction of an effective therapy with oral corticosteroids in the 1950s, the disease had a dismal natural course with a 50% mortality rate at 2 years and 100%

Etiquetado con: , , , , , , , ,
Publicado en: Médicos

UNIRSE HOY!

El registro de p y p ha sido aprobado por la Junta de revisión institucional de occidental (WIRB) y activamente es inscribir participantes.

VERSIÓN EN INGLÉS